Skip To Content



Clinical Connection


Thought leadership on the clinical impact on workers' compensation and auto no-fault.

Brand–Generic Pipeline Q1 2023

April 6, 2023 · Clinical Team

The following list represents a summary of new medications approved by the U.S. Food and Drug Administration (FDA), and first-time generics or brand alternatives that potentially may be prescribed for the treatment of a workers’ compensation or auto injury. Off-label use for the treatment of conditions outside of FDA-approved indications may not be supported by medical treatment guidelines or Optum Workers’ Compensation and Auto No-Fault.

New medications

There were no new medications relevant to workers’ compensation and/or auto injuries launched during this quarter.

First-time generics or brand alternatives

For more information about these medications, click on the link in the brand-name medication to visit the manufacturer’s website. 


Generic name Brand name Strength(s) and dosage form(s) Use/indication* Launch date
Diclofenac potassium Cambia® 50 mg oral solution Acute treatment of migraine 1/04/2023
Topiramate Trokendi XR® 25 mg, 50 mg, 100 mg
extended-release capsules
Preventive treatment of migraine; various seizures 1/04/2023
Lurisadone Latuda® 20 mg, 40 mg, 60 mg,
80 mg and 120 mg tablets
Schizophrenia; major depressive episode associated with bipolar I disorder 2/20/2023
Fluticasone/salmeterol Advair HFA® 45 mcg/21 mcg,
115 mcg/21 mcg, and
230 mcg/21 mcg per actuation
Asthma 3/01/2023

*This list is focused on medications related to workers’ compensation and/or auto injuries and may not include all medications made available this quarter
200 mg XR strength is not available in generic


If you have any questions, please contact your account manager, clinical liaison, or our Clinical Services team at 1-877-275-7674 ext. 8612.

Clinical Connection